Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Qiufang Cheng

Internal Medicine Gaithersburg, MD Medical Doctor

NPI 1073734810 CMS profile 963417

16009 Comprint Cir, Gaithersburg, MD 20877

Open in the dashboard

General payments

$4,489

115 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Qiufang Cheng of Gaithersburg, MD is reported in the CMS Open Payments database as having received $4,489 across 115 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 88th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $464 13
2024 General $849 17
2023 General $496 15
2022 General $675 20
2021 General $277 15
2020 General $655 17
2019 General $1,073 18

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Qiufang Cheng
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Qiufang Cheng were reported at $464. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Qiufang Cheng Internal Medicine median Middle half National median
2019 $1,073 $159 $48–$570 $163
2020 $655 $119 $33–$402 $114
2021 $277 $135 $37–$521 $132
2022 $675 $141 $42–$496 $149
2023 $496 $149 $45–$519 $160
2024 $849 $154 $47–$537 $164
2025 $464 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Gilead Sciences, Inc. $2,752 95 payments
  2. Sunovion Pharmaceuticals Inc. $205 2 payments
  3. AstraZeneca Pharmaceuticals LP $179 2 payments
  4. Novo Nordisk Inc $170 3 payments
  5. Dexcom, Inc. $135 1 payment
  6. Penumbra, Inc. $129 1 payment
  7. Phathom Pharmaceuticals, Inc. $125 1 payment
  8. Amgen Inc. $125 1 payment
  9. Noven Pharmaceuticals, Inc. $125 1 payment
  10. ARS Pharmaceuticals Operations, Inc. $100 1 payment
  11. Other $445 7 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $4,449 113 payments
  2. Education $40 2 payments
Products named General payments · program years 2019–2025
  1. Vemlidy $859 9 payments
  2. Penumbra System $259 2 payments
  3. APTIOM $205 2 payments
  4. DEXCOM G7 GSS (161) $135 1 payment
  5. Livdelzi $130 1 payment
  6. VOQUEZNA $125 1 payment
  7. Prolia $125 1 payment
  8. FARXIGA $125 1 payment
  9. Xelstrym $125 1 payment
  10. NEFFY $100 1 payment
  11. Other $574 9 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 103 drugs

Part D claims

7,514

Median for Internal Medicine: 777

Drug cost

$610,074

Median for Internal Medicine: $73,373

Branded share of claims

14.9%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Vemlidy Tenofovir Alafenamide Brand 72 $119,559
Jardiance Empagliflozin Brand 78 $81,045
Tradjenta Linagliptin Brand 96 $57,436
Eliquis Apixaban Brand 62 $55,808
Linzess Linaclotide Brand 64 $35,990
Trulicity Dulaglutide Brand 12 $31,361
Farxiga Dapagliflozin Propanediol Brand 21 $22,977
Vascepa Icosapent Ethyl Brand 27 $15,593
Zenpep Lipase/Protease/Amylase Brand 27 $14,092
Restasis Cyclosporine Brand 18 $12,338

The 10 drugs with the highest cost, of 103 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 27 billing codes

Paid by Medicare

$82,918

Of which drugs: $10,767

Medicare patients

235

Average age 78

Services billed

1,636

142 women, 93 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 43%
Diabetes 40%
Osteoporosis 36%
Depression 30%
Alzheimer's or dementia 28%
Chronic kidney disease 22%
Ischemic heart disease 18%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90662 Office 65 65 $5,318
Influenza vaccine, trivalent derived from recombinant dna 90673 Office 57 57 $4,582

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

4 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Vemlidy
  • Gilead Sciences, Inc. $262
$262 72 —
VOQUEZNA
  • Phathom Pharmaceuticals, Inc. $125
$125 — —
Xelstrym
  • Noven Pharmaceuticals, Inc. $125
$125 — —
Leqembi
  • Eisai Inc. $82
$82 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

115 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Maryland

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record